Press coverage about Coherus Biosciences (NASDAQ:CHRS) has been trending somewhat positive recently, according to Accern. The research group rates the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Coherus Biosciences earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 47.17505081458 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s rankings:
Shares of Coherus Biosciences (NASDAQ:CHRS) opened at $13.70 on Friday. The firm has a market cap of $793.85, a price-to-earnings ratio of -2.53 and a beta of 3.89. Coherus Biosciences has a one year low of $8.05 and a one year high of $28.60. The company has a debt-to-equity ratio of 1.84, a quick ratio of 5.46 and a current ratio of 5.46.
Coherus Biosciences (NASDAQ:CHRS) last posted its earnings results on Monday, November 6th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.26). Coherus Biosciences had a negative return on equity of 582.31% and a negative net margin of 73.89%. sell-side analysts expect that Coherus Biosciences will post -4.39 EPS for the current year.
Several brokerages have commented on CHRS. Credit Suisse Group restated an “outperform” rating and set a $17.00 price objective (down from $24.00) on shares of Coherus Biosciences in a research report on Wednesday, September 27th. Zacks Investment Research raised shares of Coherus Biosciences from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a research note on Wednesday, January 3rd. ValuEngine raised shares of Coherus Biosciences from a “strong sell” rating to a “sell” rating in a research note on Wednesday, January 3rd. BidaskClub raised shares of Coherus Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday, December 21st. Finally, Citigroup reaffirmed a “buy” rating and set a $23.00 target price on shares of Coherus Biosciences in a research note on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $29.67.
COPYRIGHT VIOLATION WARNING: “Coherus Biosciences (CHRS) Earning Somewhat Favorable Press Coverage, Accern Reports” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/12/coherus-biosciences-chrs-earning-somewhat-favorable-press-coverage-accern-reports.html.
Coherus Biosciences Company Profile
Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.